ZA201700880B - Polymorphs of selinexor - Google Patents

Polymorphs of selinexor

Info

Publication number
ZA201700880B
ZA201700880B ZA2017/00880A ZA201700880A ZA201700880B ZA 201700880 B ZA201700880 B ZA 201700880B ZA 2017/00880 A ZA2017/00880 A ZA 2017/00880A ZA 201700880 A ZA201700880 A ZA 201700880A ZA 201700880 B ZA201700880 B ZA 201700880B
Authority
ZA
South Africa
Prior art keywords
selinexor
polymorphs
Prior art date
Application number
ZA2017/00880A
Other languages
English (en)
Inventor
Brian Clinton Austad
David G Roe
Original Assignee
Karyopharm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc
Publication of ZA201700880B publication Critical patent/ZA201700880B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA2017/00880A 2014-08-15 2017-02-03 Polymorphs of selinexor ZA201700880B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462038069P 2014-08-15 2014-08-15
PCT/US2015/045395 WO2016025904A1 (en) 2014-08-15 2015-08-14 Polymorphs of selinexor

Publications (1)

Publication Number Publication Date
ZA201700880B true ZA201700880B (en) 2020-01-29

Family

ID=53969460

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/00880A ZA201700880B (en) 2014-08-15 2017-02-03 Polymorphs of selinexor

Country Status (18)

Country Link
US (6) US10519139B2 (https=)
EP (2) EP4112615A1 (https=)
JP (3) JP6777626B2 (https=)
KR (1) KR102608259B1 (https=)
CN (3) CN111484483B (https=)
AU (4) AU2015301484B2 (https=)
CA (1) CA2957266A1 (https=)
CO (1) CO2017001884A2 (https=)
DK (1) DK3180331T3 (https=)
EA (1) EA201790384A1 (https=)
ES (1) ES2926377T3 (https=)
IL (1) IL250328B (https=)
MA (1) MA40254B1 (https=)
MX (2) MX388170B (https=)
SG (2) SG11201700789SA (https=)
UA (1) UA123535C2 (https=)
WO (1) WO2016025904A1 (https=)
ZA (1) ZA201700880B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201800171T1 (it) 2011-07-29 2018-07-17 Karyopharm Therapeutics Inc Modulatori di trasporto nucleare contenenti idrazide e loro usi
CA2872190C (en) 2012-05-09 2024-06-25 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US10202366B2 (en) 2013-03-15 2019-02-12 Karyopharm Therapeutics Inc. Methods of promoting wound healing using CRM1 inhibitors
DK3492455T3 (da) 2013-06-21 2023-08-14 Karyopharm Therapeutics Inc 1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer
CN111484483B (zh) 2014-08-15 2023-05-26 卡尔约药物治疗公司 赛灵克斯的多晶型物
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2017117535A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2017118940A1 (en) 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
WO2018129227A1 (en) 2017-01-05 2018-07-12 Watson Laboratories Inc. Novel crystalline forms of selinexor and process for their preparation
CN106831731B (zh) * 2017-01-17 2019-11-08 广州市闻皓生物科技有限公司 一种Selinexor原料药的合成方法
WO2019232724A1 (en) 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
WO2020072008A1 (en) * 2018-10-04 2020-04-09 Deva Holding Anonim Sirketi Novel solid dispersions of selinexor
CA3130107A1 (en) * 2019-03-20 2020-09-24 Johnson Matthey Public Limited Company Co-crystal forms of selinexor
KR20220004142A (ko) 2019-05-01 2022-01-11 카리오팜 쎄라퓨틱스, 인코포레이티드 Xp01 억제제 및 xp01 억제제의 제조에 사용하기 위한 중간체의 제조 방법
US20220218725A1 (en) * 2019-05-16 2022-07-14 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3808742A1 (en) 2019-10-16 2021-04-21 Sandoz AG Polymorph of selinexor
WO2022087218A1 (en) 2020-10-21 2022-04-28 Karyopharm Therapeutics Inc. Crystalline form of selinexor
CN112679477B (zh) * 2020-12-17 2021-10-26 佛山奕安赛医药科技有限公司 塞利尼索及其中间体的制备方法
WO2023122014A1 (en) * 2021-12-20 2023-06-29 Raytheon Technologies Corporation Particle enhancement of ceramic matrix composites, method of manufacture thereof and articles comprising the same
CN116675677B (zh) * 2023-08-02 2023-09-26 中国林业科学研究院林产化学工业研究所 一种c8漆酚衍生物及其制备方法和应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017398A (en) 1911-01-16 1912-02-13 John E Folsom Telegraph-key.
CS229934B2 (en) 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
KR840000529A (ko) 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
JP3111321B2 (ja) 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
IL97249A (en) 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
AU4368996A (en) 1994-11-23 1996-06-17 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
US20030018025A1 (en) 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
EP0858457A1 (de) 1995-10-20 1998-08-19 Dr. Karl Thomae GmbH 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
CA2250002C (en) 1996-04-04 2008-03-25 Shionogi & Co., Ltd. Cephem compounds and drugs containing the compounds
EP0913392B1 (en) 1996-04-25 2003-07-02 Nissan Chemical Industries, Limited Ethylene derivatives and pest controlling agents
JP4054992B2 (ja) 1996-04-25 2008-03-05 日産化学工業株式会社 エチレン誘導体および有害生物防除剤
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
WO1999050264A1 (en) 1998-03-30 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Quinazoline derivatives
US6743585B2 (en) 1999-09-16 2004-06-01 Agilent Technologies, Inc. Methods for preparing conjugates
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
EP1335898B1 (en) 2000-09-29 2005-11-23 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
EP1429765A2 (en) 2001-09-14 2004-06-23 Methylgene, Inc. Inhibitors of histone deacetylase
AU2003287965A1 (en) 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
JP4145230B2 (ja) 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
NZ540381A (en) 2002-11-01 2007-11-30 Takeda Pharmaceutical 5-membered aromatic heterocycle derivatives as prophylactic and therapeutic agents for treating neuropathy
ATE552253T1 (de) 2002-11-08 2012-04-15 Novartis Int Pharm Ltd 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren
EP1599447A1 (en) 2003-02-28 2005-11-30 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
MY149038A (en) 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
MX2007001634A (es) 2004-08-11 2007-04-23 Kyorin Seiyaku Kk Nuevo derivado de acido amino benzoico ciclico.
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
EP1849465A4 (en) 2005-02-18 2008-12-24 Takeda Pharmaceutical AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR
US8637559B2 (en) * 2005-11-15 2014-01-28 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition
JP2007210929A (ja) 2006-02-09 2007-08-23 Sankyo Co Ltd ウレア化合物を含有する医薬
AR059955A1 (es) 2006-03-09 2008-05-14 Eisai R&D Man Co Ltd Compuestos policiclicos no peptidicos, medicamentos que los contienen, y usos para prevenir o tratar enfermedades causadas por la produccion de beta amiloide
KR101495611B1 (ko) 2006-04-07 2015-02-25 메틸진 인코포레이티드 히스톤 데아세틸라아제의 억제제
CN101466687B (zh) 2006-04-18 2012-04-11 日本化学医药株式会社 过氧化物酶体增殖剂激活受体δ的激活剂
KR101130380B1 (ko) 2006-06-13 2012-04-23 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 헤테로시클릭 비뉴클레오시드 화합물, 그의 제조방법, 약학적 조성물 및 항바이러스성 약제로서의 용도
PL2054411T3 (pl) 2006-07-27 2015-02-27 Amorepacific Corp Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
AU2007292155B2 (en) 2006-09-05 2012-11-01 Kyowa Kirin Co., Ltd. Imidazole derivative
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
US7795457B2 (en) 2007-02-26 2010-09-14 Kosan Biosciences Incorporated Carbamate compounds
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
US8106083B2 (en) 2008-08-08 2012-01-31 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
CN102480969A (zh) 2009-07-09 2012-05-30 科锐医疗有限公司 伤口愈合和瘢痕调制方法
US8518968B2 (en) 2009-12-04 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
CN103002742B (zh) 2010-03-05 2016-07-13 卡尔约药物治疗公司 核转运调节剂及其应用
JP6106605B2 (ja) 2011-01-17 2017-04-05 カリオファーム セラピューティクス,インコーポレイテッド オレフィン含有核輸送調節剤およびその使用
US9428490B2 (en) 2011-07-29 2016-08-30 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
SMT201800171T1 (it) 2011-07-29 2018-07-17 Karyopharm Therapeutics Inc Modulatori di trasporto nucleare contenenti idrazide e loro usi
WO2013020024A2 (en) 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
CA2872190C (en) 2012-05-09 2024-06-25 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US20160016916A1 (en) 2013-03-15 2016-01-21 Karyopharm Therapeutics Inc. Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof
US10202366B2 (en) * 2013-03-15 2019-02-12 Karyopharm Therapeutics Inc. Methods of promoting wound healing using CRM1 inhibitors
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
DK3492455T3 (da) 2013-06-21 2023-08-14 Karyopharm Therapeutics Inc 1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer
WO2015073908A1 (en) * 2013-11-15 2015-05-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method for selecting cancer treatment regimen
US10969391B2 (en) 2014-07-11 2021-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing hematological cancers
KR20170032244A (ko) * 2014-07-26 2017-03-22 선샤인 레이크 파르마 컴퍼니 리미티드 Cdk 저해제로서 2-아미노-피리도[2,3-d]피리미딘-7(8h)-온 유도체 및 그 용도
CN111484483B (zh) 2014-08-15 2023-05-26 卡尔约药物治疗公司 赛灵克斯的多晶型物
CN108348547B (zh) 2015-08-28 2023-09-22 纽约市哥伦比亚大学信托人 用于匹配肿瘤学特征的系统和方法
WO2017117535A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2017118940A1 (en) 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
JP6765198B2 (ja) 2016-03-10 2020-10-07 パナソニック株式会社 潜熱蓄熱材及びそれを用いる蓄熱システム
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
WO2018129227A1 (en) * 2017-01-05 2018-07-12 Watson Laboratories Inc. Novel crystalline forms of selinexor and process for their preparation
CN106831731B (zh) 2017-01-17 2019-11-08 广州市闻皓生物科技有限公司 一种Selinexor原料药的合成方法
SG11202110589PA (en) 2019-03-27 2021-10-28 Karyopharm Therapeutics Inc Biomarkers for selinexor
EP3808742A1 (en) 2019-10-16 2021-04-21 Sandoz AG Polymorph of selinexor
ES3001533T3 (en) 2019-12-06 2025-03-05 Bae Systems Plc Light source
WO2022087218A1 (en) 2020-10-21 2022-04-28 Karyopharm Therapeutics Inc. Crystalline form of selinexor

Also Published As

Publication number Publication date
EA201790384A1 (ru) 2017-08-31
US20230242517A1 (en) 2023-08-03
US20220135545A1 (en) 2022-05-05
MX388170B (es) 2025-03-19
AU2021286266A1 (en) 2022-01-06
US11807629B2 (en) 2023-11-07
CN107072992A (zh) 2017-08-18
US20180215733A1 (en) 2018-08-02
AU2021286266B2 (en) 2024-02-01
AU2015301484B2 (en) 2020-02-20
US11078190B2 (en) 2021-08-03
US20200283419A1 (en) 2020-09-10
AU2020203246B2 (en) 2021-09-16
AU2024202835A1 (en) 2024-05-23
MA40254A (fr) 2021-05-19
MX2021014128A (es) 2022-01-04
AU2015301484A1 (en) 2017-03-02
DK3180331T3 (da) 2022-09-12
IL250328A0 (en) 2017-03-30
US12371420B2 (en) 2025-07-29
ES2926377T3 (es) 2022-10-25
JP7218323B2 (ja) 2023-02-06
KR102608259B1 (ko) 2023-11-29
MX2017002013A (es) 2017-05-12
EP3180331B1 (en) 2022-06-08
US11753401B2 (en) 2023-09-12
MA40254B1 (fr) 2022-09-30
SG10201808624VA (en) 2018-11-29
CN111484483A (zh) 2020-08-04
IL250328B (en) 2022-05-01
SG11201700789SA (en) 2017-02-27
KR20170043561A (ko) 2017-04-21
US20230242516A1 (en) 2023-08-03
EP3180331A1 (en) 2017-06-21
US20240208943A1 (en) 2024-06-27
US10519139B2 (en) 2019-12-31
CN107072992B (zh) 2020-03-10
CN111484483B (zh) 2023-05-26
US11746102B2 (en) 2023-09-05
JP2023052622A (ja) 2023-04-11
CN111481553A (zh) 2020-08-04
NZ728850A (en) 2024-03-22
WO2016025904A1 (en) 2016-02-18
CO2017001884A2 (es) 2017-07-19
JP2020143144A (ja) 2020-09-10
CN111481553B (zh) 2023-09-01
EP4112615A1 (en) 2023-01-04
UA123535C2 (uk) 2021-04-21
JP2017527549A (ja) 2017-09-21
CA2957266A1 (en) 2016-02-18
JP7558310B2 (ja) 2024-09-30
JP6777626B2 (ja) 2020-10-28
AU2020203246A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
IL273230A (en) Preparation of carbamoylpyridone-polycyclic compounds
ZA201700880B (en) Polymorphs of selinexor
HU4602U (en) Set of saggar assembly
SI3524234T1 (sl) Trdne oblike sofosbuvira
PL3113773T3 (pl) Krystaliczne postaci grapiprantu
IL246979A0 (en) Crystalline forms of sofosbuvir
ZA201706282B (en) Solid forms of menaquinols
HU4603U (en) Set of saggar assembly
IL265180B (en) New polymorphs and new solid states of tiacomycin b
ZA201608686B (en) Interseparation of metals
SI3253769T1 (sl) Novi polimorfi
IL249130B (en) Preparation of piperidine-4-carbothioamide
GB2544217B (en) Chlorination of sucrose-6-esters
GB201403438D0 (en) Polymorphs
TWM489811U (en) Structural improvement of tube
IL249332A0 (en) Crystalline forms of sofosbuvir
PL3137475T3 (pl) Oczyszczanie epidaunorubicyny
GB201416951D0 (en) Method of synthesis
GB201414267D0 (en) Chlorination of sucrose-6-esters
GB201418773D0 (en) Mechanism of action
GB201404705D0 (en) Theory of Conceptual art